"4.2. D\u00E1vkov\u00E1n\u00ED a zp\u016Fsob pod\u00E1n\u00ED"@cs . "004.002" . . "U\u017E\u00EDv\u00E1 se 1 tableta l\u00E9\u010Div\u00E9ho p\u0159\u00EDpravku 2 \u2013 3x denn\u011B (co\u017E odpov\u00EDd\u00E1 500 mg a\u017E 750 mg kyseliny aminomethylbenzoov\u00E9 denn\u011B).\nDal\u0161\u00ED d\u00E1vky by m\u011Bly b\u00FDt upraveny na z\u00E1klad\u011B \u00FA\u010Dinku a v\u00FDsledk\u016F test\u016F krevn\u00ED sr\u00E1\u017Elivosti.\nMaxim\u00E1ln\u00ED d\u00E1vka 4 tablety p\u0159\u00EDpravku Pamba (co\u017E odpov\u00EDd\u00E1 1000 mg kyseliny aminomethylbenzoov\u00E9 denn\u011B) by nem\u011Bla b\u00FDt p\u0159ekro\u010Dena.\nRen\u00E1ln\u00ED insuficience\nV\u00A0sou\u010Dasn\u00E9 dob\u011B nejsou k\u00A0dispozici studie o pou\u017Eit\u00ED p\u0159i ren\u00E1ln\u00EDm po\u0161kozen\u00ED. Ov\u0161em vzhledem k\u00A0tomu, \u017Ee eliminace prob\u00EDh\u00E1 p\u0159ev\u00E1\u017En\u011B ren\u00E1ln\u00ED cestou, je pravd\u011Bpodobn\u00E9, \u017Ee by mohlo doj\u00EDt ke kumulaci. Proto je indikov\u00E1na kontrola clearance kreatininu.\nStar\u0161\u00ED pacienti:\nV\u00A0sou\u010Dasn\u00E9 dob\u011B nejsou k\u00A0dispozici studie o pou\u017Eit\u00ED u star\u0161\u00EDch pacient\u016F.\nD\u011Bti:\nV\u00A0sou\u010Dasn\u00E9 dob\u011B nejsou k\u00A0dispozici studie o pou\u017Eit\u00ED u d\u011Bt\u00ED.\nZp\u016Fsob a d\u00E9lka pod\u00E1v\u00E1n\u00ED:\nTablety se polykaj\u00ED vcelku po j\u00EDdle a zapij\u00ED se vodou.\nD\u00E9lku l\u00E9\u010Dby ur\u010D\u00ED l\u00E9ka\u0159.\n"@cs . . . . . . . . . .